April 18 Prometic Life Sciences Inc
* FDA confirms Prometic's PBI-4050 IPF clinical trial design
* Prometic Life Sciences Inc - Prometic to also conduct placebo controlled phase 2/3 PBI-4050 monotherapy clinical trial
* Prometic Life Sciences Inc - FDA concurs with add-on placebo controlled phase 2/3 clinical trial for PBI-4050 in combination with Nintedanib Source text for Eikon: Further company coverage:
WORLD NEWS SCHEDULE AT 1800 GMT/2 PM ET
Iraqi forces free hundreds of civilians in Mosul Old City battles as death toll mounts
CEO of Raytheon's Forcepoint eyes IPO -Boersen-Zeitung
FRANKFURT, June 24 U.S. missile maker Raytheon's cybersecurity unit could thrive were it to be listed separately, the head of the unit, Forcepoint, told German business daily Boersenzeitung in an interview published on Saturday.